Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for BioXcel Therapeutics, Inc. (BTAI : NSDQ)

• Company Description    BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. BioXcel Therapeutics Inc. is based in the United States. Number of Employees: 80

• Price / Volume Information    Yesterday's Closing Price: $2.29 Daily Weekly Monthly 20 Day Moving Average: 1,210,472 shares Shares Outstanding: 16.01 (millions) Market Capitalization: $36.66 (millions) Beta: 0.18 52 Week High: $13.28 52 Week Low: $1.17 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.63% -18.13% 12 Week 34.71% 27.80% Year To Date -61.72% -66.57%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 555 LONG WHARF DRIVE - NEW HAVEN,CT 06511 USA ph: 475-238-6837 fax: - ekopp@bioxceltherapeutics.com http://www.bioxceltherapeutics.com

• General Corporate Information    Officers Vimal Mehta - Chief Executive Officer; President; and Director Peter Mueller - Chairman of the Board of Directors Richard Steinhart - Senior Vice President and Chief Financial Officer June Bray - Director Sandeep Laumas - Director Peer Information BioXcel Therapeutics, Inc. (CORR.) BioXcel Therapeutics, Inc. (RSPI) BioXcel Therapeutics, Inc. (CGXP) BioXcel Therapeutics, Inc. (BGEN) BioXcel Therapeutics, Inc. (GTBP) BioXcel Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09075P204 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 16.01 Most Recent Split Date: 2.00 (0.06:1) Beta: 0.18 Market Capitalization: $36.66 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.82 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.93 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 40.19% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 42.24 EPS Growth vs. Year Ago Period: 27.08% vs. Previous Quarter: -63.33% Sales Growth vs. Year Ago Period: -89.13% vs. Previous Quarter: -28.57% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - -134.45 03/31/25 - -83.80 Current Ratio 09/30/25 - - 06/30/25 - 0.76 03/31/25 - 1.48 Quick Ratio 09/30/25 - - 06/30/25 - 0.74 03/31/25 - 1.45 Operating Margin 09/30/25 - - 06/30/25 - -5,869.82 03/31/25 - -2,163.18 Net Margin 09/30/25 - - 06/30/25 - -5,869.82 03/31/25 - -2,163.18 Pre-Tax Margin 09/30/25 - - 06/30/25 - -5,869.82 03/31/25 - -2,163.18 Book Value 09/30/25 - - 06/30/25 - -16.26 03/31/25 - -16.49 Inventory Turnover 09/30/25 - - 06/30/25 - 2.53 03/31/25 - 1.50 Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - -

Powered by Zacks Investment Research ©